In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valuing Infectious Disease Deals: EBI's new Deal Valuation Tool

Executive Summary

The growing problem of antibiotic resistance has forced big drug companies to take renewed interest in novel anti-infectives. Although the number of deals signed thus far in 2011 in this therapeutic area is lower than in prior years, licensing commitments have remained strong. Different deal structure scenarios based on the recent platform alliance between Sanofi and Rib-X are taken through EBI's new Strategic Transactions Deal Valuation Tool.

You may also be interested in...



Tracking Big Pharma's Appetite For Regional Deals

A review of Big Pharma regional dealmaking in 2006-2010 shows a slower uptick in the number of alliances than the steady year-over-year growth seen from 2001-2006.

Giddy Emphasizes Shape To Differentiate Its OTC ED Device In Crowded And Growing Market

Designed to decrease venous leak from the corpora cavernosa, Giddy makes its Eddie device in oblong shape that opens at one point into two S-forms. Elastic bands are placed around the S-forms to pull the shape together at variable tensions.

How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell

Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel